Type II CRISPR/Cas9 approach in the oncological therapy

Table 1 Novel gene editing-based therapies

Disease	Target	Reference
Duchenne Muscular Dystrophy	Dystrophin	[38,39,40]
Cystic Fibrosis	Cystic Fibrosis Transmembrane Conductance Regulator	[41]
HPV	E6 & E7	[42;43]
HBV	HBsAg & HBx	[44]
EBV	EBNA1, EBNA3C & LMP-1	[45]
	BART miRNA	[46]
AIDS	Gag/Pol - Rev/Env	[47]
	LTR-1, LTR-3, GagD & PolB	[48]
β-thalassaemia	β-/γ-globin	[49]
Leber congenital amaurosis	CEP290	[50]
Haemophilia	F9	[51]
Non-small Cell Lung Cancer	PD-1	[53]
Prostate Carcinoma	PD-1	[55]
Bladder Carcinoma	PD-1	[55]

On the left column it is reported the disease, on the central one the target gene and on the right one the reference number

ISSN: 1756-9966